Patients with malignant or pre-malignant cervical lesion have increased risk of becoming hepatitis B carrier

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 1, 2007, Pages 77-81

  Siu, Shing Shun N ^a   Cheung, T H ^a   Chan, P K S ^a   Lin, C K ^b   Lo, K W K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Hong Kong Red Cross Blood Transfusion Service   (Hong Kong)

Author keywords

Cervical carcinoma; Hepatitis B virus; Hepatocellular carcinoma; Human papillomavirus; Immunogenetics

Indexed keywords

HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIBODY;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; NEOPLASM; PRIORITY JOURNAL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; VIRUS INFECTION; WART VIRUS;

ADULT; AGED; CARRIER STATE; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; INCIDENCE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 34247507083     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. zur Hausen H.: Viruses in Human Cancers. Eur. J. Can. 35: 1174-1181, 1999.
2. Crum C.P., Rivera M.N.: Vaccines for Cervical Cancer. Cancer J. 9: 368-376, 2003.
3. Bekkers R.L., Massuger L.F., Bulten J., Melchers W.J.: Epidemiological and Clinical Aspects of Human Papillomavirus Detection in The Prevention of Cervical Cancer. Rev. Med. Virol. 14: 95-105, 2004.
4. Godkin A., Davenport M., Hill A. V.S.: Molecular Analysis of HLA Class II Associations With Hepatitis B Virus Clearance And Vaccine Nonresponsiveness. Hepatology 41: 1383-1390, 2005.
5. Lo Y.M., Lo E.S., Mehal W.Z. et al.: Geographical Variation in Prevalence of Hepatitis B Virus DNA in HBsAg Negative Patients. J. Clin. Pathol. 46: 304-308, 1993.
6. Hong Kong Cancer Registry, Hospital Authority. Available at: http://www3.ha.org.hk/cancereg/stat.asp Retrieved 1st May, 2006.
7. Chan P.K.S., Chang A.R., Tam W.H., Cheung J.L.K., Cheng A.F.: Prevalence and Genotype Distribution of Cervical Human Papillomavirus Infection: Comparison Between Pregnant Women and Non-Pregnant Controls. J. Med. Virol. 67: 583-588, 2002.
8. Maciag P.C., Schlecht N.F., Souza P.S., Franco E.L., Villa L.L., Petzl-Erler M.L.: Major Histocompatibility Complex Class II Polymorphisms and Risk of Cervical Cancer and Human Papillomavirus Infection in Brazilian Women. Cancer Epidemiol. Biomarkers Prev. 9: 1183-1191, 2000.
9. Davidson E.J., Davidson J.A., Sterling J.C., Baldwin P.J.W., Kitchener H.C., Stern P.L.: Association between Human Leukocyte Antigen Polymorphism and Human Papillomavirus 16 positive Vulval intraepithelial Neoplasia in British women. Cancer Res. 63: 400-403, 2003.
10. Maiman M., Fruchter R.G., Serur E., Remy J.C., Feuer G., Boyce J.: Human Immunodeficiency Virus Infection and Cervical Neoplasia. Gynecol. Oncol. 38: 377-382, 1990.
11. Han R., Breitburd F., Marche P.N., Orth G.: Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes. Nature 356: 66-68, 1992.
12. Wang S.S., Wheeler C.M., Hildesheim A. et al.: Human Leukocyte Antigen Class I and II Alleles and Risk of Cervical Neoplasia: Results from a Population-Based Study in Costa Rica. J. Infect. Dis. 184: 1310-1314, 2001.
13. Ahn S.H., Han K.H., Park J.Y. et al.: Association between Hepatitis B Virus Infection and HLA-DR Type in Korea. Hepatology 31: 1371-1373, 2000.
14. Baez-Astua A., Herraez-Hernandez E., Garbi N. et al: Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J. Virol. 79; 12807-12817, 2005.
15. Ostor A.G.: Natural History of Cervical Intraepithelial Neoplasia: A Critical Review. Int. J. Gynecol. Pathol. 12; 186-192, 1993.
16. Zoodsma M., Nolte I.M., Te Meerman G.J., De Vries E.G., Van der Zee A.G.: HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. Int. J. Oncol. 26: 769-784, 2005.
17. Hohler T., Gerken G., Notghi A. et al.: HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J. Hepatol. 26: 503-507, 1997.
18. Thio C.L., Carrington M., Marti D. et al.: Class II HLA Alleles and Hepatitis B Virus Persistence in African Americans. J. Infect. Dis. 179: 1004-1006, 1999.
19. Thursz M.R., Kwiatkowski D., Allsopp C.E.M., Greenwood B.M., Thomas H.C., Hill A.V.S.: Association between an MHC class II allele and Clearance of Hepatitis B virus in the Gambia. N. Engl. J. Med. 332: 1065-1069, 1995.
20. Diepolder H.M., Jung M.C., Keller E. et al: A Vigorous Virus-Specific CD4+ T Cell Response may Contribute to the Association of HLA-DR13 With Viral Clearance in Hepatitis B. Clin. Exp. Immunol. 113: 244-251, 1998.
21. Chan D.P.C., Cheung T.H., Tam A.O.Y. et al.: Risk Association between Human Leukocyte Antigen-A Allele and High-Risk Human Papillomavirus Infection for Cervical Neoplasia in Chinese Women. J. Infect. Dis. 192: 1749-1756, 2005.